Advertisement
UK markets closed

  • FTSE 100

    8,237.72
    -34.74 (-0.42%)
     

  • FTSE 250

    20,442.35
    -56.35 (-0.27%)
     

  • AIM

    772.57
    +0.19 (+0.02%)
     

  • GBP/EUR

    1.1824
    +0.0002 (+0.02%)
     

  • GBP/USD

    1.2634
    -0.0026 (-0.20%)
     

  • Bitcoin GBP

    50,701.32
    -129.85 (-0.26%)
     

  • CMC Crypto 200

    1,321.79
    -38.54 (-2.83%)
     

  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     

  • DOW

    39,150.33
    +15.53 (+0.04%)
     

  • CRUDE OIL

    80.59
    -0.14 (-0.17%)
     

  • GOLD FUTURES

    2,334.70
    +3.50 (+0.15%)
     

  • NIKKEI 225

    38,596.47
    -36.53 (-0.09%)
     

  • HANG SENG

    18,028.52
    -306.78 (-1.67%)
     

  • DAX

    18,163.52
    -90.68 (-0.50%)
     

  • CAC 40

    7,628.57
    -42.77 (-0.56%)
     

Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference

Third Harmonic Bio
·1-min read

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 7:30 a.m. ET.

A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event.

About Third Harmonic Bio, Inc.
Third Harmonic Bio is a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate, THB335, is a titratable, oral, small molecule inhibitor that is currently in a Phase 1 clinical trial. For more information, please visit the Third Harmonic Bio website: www.thirdharmonicbio.com.

Investor and Media Contact:
Lori Murray
lori.murray@thirdharmonicbio.com